CAG方案治疗低增生性急性髓系白血病29例

Clinical observation of CAG regimen in treatment of 29 patients with hypocellular acute myelogenousleukemia

目的观察CAG方案治疗低增生性急性髓系白血病（AML）的临床疗效。方法对29例低增生性AML患者采用CAG方案，阿柔比星（Acla）14mg／m^2，第1天至第4天，静脉注射；阿糖胞苷（Ara—C）10mg／m^2，第1天至第14天，每12h皮下注射；粒细胞集落刺激因子（G—CSF）200μg／m^2，第1天至第14天，皮下注射，并于第1次注射Ara—C之前12h开始使用，最后一次注射Ara—C前12h停用；当中性粒细胞〉10×10^9／L时，暂时减少或停用G—CSF。结果29例患者中完全缓解（CR）14例（48．3％），部分缓解（PR）7例（24．1％），总有效率72．4％，治疗失败，讯（NR）7例，早期死亡1例。结论CAG方案治疗低增生性AML安全有效，可有效缩短外周血粒细胞减少的时间，降低化疗相关死亡率。

Objective To investigate the clinic effect of hypocellular acute myelogenous leukemia （AML） patients with CAG regimen. Methods 29 cases with hypocellular AML were treated with CAG regimen. Results There were 14 cases achieved complete remission （CR）, accounting for 48.3 %, 7 cases partial remission （PR）, accounting for 24.1%. The total effective rate was 72.4 %, inducing 7 cases of NR, one case dead in early time. Conclusion CAG regimen has been proved to be effective in shortening the period of reduced peripheral blood granulocytes and decreasing the death rate related to chemotherapy, hence, a secure and effective therapy in treating hypocellular AML.